23andMe Holding Co. Stock News

An analyst calls 23andMe's 11 million sample database unique and unprecedented.

These stocks are far from sure things, but their potential is undeniable.

23andMe is well known for their services around DNA testing, ancestry mapping, and genetic data. By collaborating with GlaxoSmithKline, the companies can better use 23andMe's 11.6 million genotyped cu

23andMe CEO Anne Wojcicki joined CNBC's Jim Cramer on Wednesday's episode of "Mad Money," discussing the company's efforts around therapeutic development.

23andMe CEO Anne Wojcicki joins 'Influencers with Andy Serwer' to discuss the politicization of medicine amid the COVID-19 pandemic.

Backed by its growing genetic database, 23andMe could take its business in a number of lucrative directions.

Many recent SPAC IPOs have been hammered, and these two could be worth a closer look.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Cathie Wood continues to pick up stocks through her ARK Invest ETFs and we're taking a look at some of their top investments for Tuesday. The post Cathie Wood Stocks: What Names Is ARK Invest CEO Buyi

23andMe (ME) stock is rising higher on Tuesday after Credit Suisse weighed in on the personal genomics and biotechnology company. The post ME Stock: The Credit Suisse Call Giving 23andMe a Boost Today

It's no great secret why Credit Suisse likes 23andMe.

23andMe Holding Co. (NASDAQ:ME) shares are trading higher by 6.6% at $7.77 Tuesday morning after Credit Suisse initiated coverage on the stock with an Outperform rating and announced a $13 price tar

23andMe Holding's (ME) CEO Anne Wojcicki on Q1 2022 Results - Earnings Call Transcript

Consumer genetics company 23andMe ME, -3.29% posted its first quarterly earnings as a public company on Friday, after it merged with Richard Branson's pecial-purpose acquisition corporation, or SPAC,

First quarter revenue up 23% over prior year Strong cash balance of $770 million Continuing to advance therapeutics portfolio to drive future revenue growth